Table 4.
Predictors of ΔVAS
| OR (95% CI) | P-valuea | |
|---|---|---|
| Proband | 1.25 (0.76–1.74) | 0.380 |
| Time between paired ESTs (per day change) | 1.00 (1.00–1.00) | 0.301 |
| Use of any antiarrhythmic drug vs. no treatmentb | 3.52 (2.46–4.57) | 0.020 |
| Type of antiarrhythmic treatment (reference: no treatment)b | ||
| ȃBeta-blocker monotherapy | 3.24 (2.11–4.37) | 0.041 |
| ȃBeta-blocker and flecainide | 3.96 (2.14–4.35) | 0.015 |
| ȃBeta-blocker, flecainide, and LCSD | 3.94 (1.99–4.50) | 0.032 |
| Age at the first EST in years | 1.00 (1.00–1.00) | 0.152 |
| Center: Mayo Clinic (reference: Amsterdam UMC) | 0.85 (0.36–1.34) | 0.522 |
| Change from morning to afternoon (reference: no change) | 0.91 (0.49–1.33) | 0.668 |
| Bike protocol (reference: treadmill protocol) | 1.14 (0.67–1.62) | 0.579 |
| Change in reason of stop EST (reference: no change) | 1.62 (0.85–2.39) | 0.218 |
| RYR2 variant classification (reference: uncertain significance) | ||
| ȃPathogenic | 1.27 (0.72–1.82) | 0.911 |
| ȃLikely pathogenic | 1.04 (0.41–1.67) | 0.392 |
| Body weight difference in kg | 0.98 (0.93–1.03) | 0.381 |
| Difference in maximum heart rate in b.p.m. | 1.04 (1.01–1.06) | 0.003 |
CI, confidence interval; LCSD, left cardiac sympathetic denervation; OR, odds ratio; VAS, ventricular arrhythmia score.
The P reflects the level of significance corresponding to the estimate of the cumulative link mixed model or generalized linear mixed model, as appropriate, taking repeated measures per individual into account.
OR and P-values are based on the estimate of the generalized linear mixed model, because the proportional odds assumption of the cumulative link mixed model was violated.